Physician profile
Aaron Chen
NPI 1780043703
$58,955.03
in general payments reported to CMS, 2019-2025
35 companies · $52K in 2025
The $52K reported for 2025 was more than what 96% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,927 · 2020: $606 · 2021: $397 · 2022: $477 · 2023: $406 · 2024: $3,126 · 2025: $52K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $21K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Food and Beverage: $6,953 · Travel and Lodging: $6,320 · Education: $202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $21,450.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,623.00 |
| Food and Beverage | $6,953.19 |
| Travel and Lodging | $6,320.14 |
| Education | $202.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Solta Medical, A Division of Bausch Health US, LLC | $41,401.77 | 2025 | Clear+Brilliant |
| Galderma Laboratories, L.P. | $6,589.19 | 2022-2025 | Aklief, Nemluvio |
| Shire North American Group INC | $1,440.00 | 2019 | |
| Musculoskeletal Transplant Foundation INC. | $1,328.25 | 2025 | |
| Abbvie INC. | $1,237.56 | 2023-2025 | Botox |
| Lilly USA, LLC | $751.41 | 2020-2025 | Olumiant, Taltz, Ebglyss |
| Genzyme Corporation | $720.83 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $576.84 | 2024-2025 | Zoryve |
| Leo Pharma INC. | $536.21 | 2024-2025 | Adbry, Anzupgo |
| Pfizer INC. | $475.53 | 2019-2025 | |
| Janssen Biotech, INC. | $452.50 | 2020-2025 | Tremfya |
| Dermavant Sciences, INC. | $440.18 | 2023-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $351.73 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $318.38 | 2021-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $303.62 | 2019-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $278.15 | 2019-2025 | Bimzelx |
| Incyte Corporation | $225.45 | 2021-2025 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $223.11 | 2019-2025 | Jublia, Cabtreo, Siliq |
| Amgen INC. | $179.34 | 2020-2025 | Otezla, Otezla |
| Almirall LLC | $170.99 | 2024 | Klisyri |
| E.R. Squibb & Sons, L.L.C. | $165.97 | 2024-2025 | Sotyktu |
| Sanofi-Aventis U.S. LLC | $163.95 | 2021-2022 | |
| Vyne Pharmaceuticals INC. | $99.53 | 2020-2021 | |
| Organon LLC | $95.26 | 2025 | Vtama |
| Celgene Corporation | $76.52 | 2019 | |
| Paratek Pharmaceuticals, INC. | $58.41 | 2021-2023 | Nuzyra |
| Genentech USA, INC. | $55.09 | 2025 | Xolair |
| Smith+Nephew, INC. | $50.16 | 2021-2022 | |
| Kyowa Kirin, INC. | $41.19 | 2020-2023 | Poteligeo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.87 | 2023 | Spevigo |
| Helsinn Therapeutics (U.S.), INC. | $31.30 | 2022-2023 | Valchlor |
| Merz North America, INC. | $25.86 | 2024 | |
| Biofrontera INC. | $22.31 | 2020 | |
| Cipher Pharmaceuticals US LLC | $16.06 | 2025 | Spinosad, Natroba |
| Astrazeneca Pharmaceuticals LP | $13.51 | 2024 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.